Search Result

Results for "

BRD2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AMPK (1) Androgen Receptor (1) Apolipoprotein (1) Apoptosis (11) Autophagy (1) Bcl-2 Family (1) c-Myc (6) CDK (2) Drug Isomer (1) E3 Ligase Ligand-Linker Conjugates (2) Epigenetic Reader Domain (85) ERK (1) Gli (1) Hedgehog (1) Histone Acetyltransferase (1) HIV (1) Interleukin Related (2) Ligands for Target Protein for PROTAC (6) Molecular Glues (4) NF-κB (1) PAK (1) PARP (1) PI3K (1) Polo-like Kinase (PLK) (1) PROTACs (28) Proteasome (1) Proteasome Cap Targeting Chimeras (1) Reference Standards (4) SARS-CoV (1) Small Interfering RNA (siRNA) (3) STAT (1) TNF Receptor (1)
By Research Areas:	Cancer (76) Infection (2) Inflammation/Immunology (16) Metabolic Disease (2) Neurological Disease (3)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Antibodies

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-100972

ARV-771 25+ Cited Publications	PROTACs Epigenetic Reader Domain	Cancer
ARV-771 is a potent BET PROTAC based on E3 ligase von Hippel-Lindau with K_ds of 34 nM, 4.7 nM, 8.3 nM, 7.6 nM, 9.6 nM, and 7.6 nM for *BRD2(1), BRD2(2), BRD3(1), BRD3(2), BRD4(1), and BRD4(2)*, respectively .

HY-15743

Birabresib Maximum Cited Publications 39 Publications Verification OTX-015; MK-8628	Epigenetic Reader Domain	Cancer
Birabresib (OTX-015) is a potent bromodomain (BRD2/3/4) inhibitor with IC₅₀s ranging from 92 to 112 nM.

HY-107425

MZ 1 20+ Cited Publications	PROTACs Epigenetic Reader Domain	Cancer
MZ 1 is a PROTAC connected by ligands for von Hippel-Lindau and *BRD4. MZ 1 potently and rapidly induces reversible, long-lasting, and selective removal of BRD4 over BRD2* and BRD3. K_ds of 382/120, 119/115, and 307/228 nM for **BRD4 BD1/2*, BRD3 BD1/2, and BRD2* BD1/2, respectively .

HY-13235

I-BET151 25+ Cited Publications GSK1210151A	Epigenetic Reader Domain	Cancer
I-BET151 (GSK1210151A) is a BET bromodomain inhibitor which inhibits *BRD4, BRD2, and BRD3* with pIC₅₀ of 6.1, 6.3, and 6.6, respectively ^[2].

HY-112090

ABBV-744 5+ Cited Publications	Epigenetic Reader Domain HIV	Infection Inflammation/Immunology Cancer
ABBV-744 is a first-in-class, orally active and selective inhibitor of the BDII domain of BET family proteins with IC₅₀ values ranging from 4 to 18 nM for BRD2, BRD3, BRD4 and BRDT. ABBV-744 is primarily metabolized by CYP3A4 with agent-like properties enable the investigation of its antitumor efficacy and tolerability .

HY-136570

GSK778 1 Publications Verification iBET-BD1	Epigenetic Reader Domain Apoptosis	Inflammation/Immunology Cancer
GSK778 (iBET-BD1), a chemical probe, is a potent and selective BD1 bromodomain inhibitor of the BET proteins, with IC₅₀s of 75 nM (BRD2 BD1), 41 nM (BRD3 BD1), 41 nM (BRD4 BD1), and 143 nM (BRDT BD1), respectively. GSK778 phenocopies the effects of pan-BET inhibitors in cancer models .

HY-13960

GSK1324726A 5+ Cited Publications I-BET726	Epigenetic Reader Domain Apoptosis	Cancer
GSK1324726A is a novel, potent, and selective inhibitor of BET proteins with high affinity to *BRD2* (IC₅₀=41 nM), *BRD3* (IC₅₀=31 nM), and *BRD4* (IC₅₀=22 nM).

HY-141438

SIM1 1 Publications Verification	PROTACs Epigenetic Reader Domain	Cancer
SIM1 is a potent von Hippel-Lindau (VHL)-based trivalent PROTAC capable of degradation for all BET family members, with preference for *BRD2* degradation (IC₅₀=1.1 nM; Kd=186 nM). SIM1 shows sustained anti-cancer activity .

HY-111422

PLX51107 3 Publications Verification	Epigenetic Reader Domain	Cancer
PLX51107 is a potent and selective BET inhibitor, with K_ds of 1.6, 2.1, 1.7, and 5 nM for BD1 and 5.9, 6.2, 6.1, and 120 nM for BD2 of BRD2, BRD3, BRD4, and BRDT, respectively; PLX51107 also interacts with the bromodomains of CBP and EP300 (K_d, in the 100 nM range).

HY-162514

BBC0403	Epigenetic Reader Domain	Inflammation/Immunology
BBC0403 is a selective *BRD2* inhibitor with K_ds of 7.64 μM and 41.37 μM for **BRD2 (BD2)** and BRD2 (BD1), respectively. BBC0403 exhibitS higher binding specificity for BRD2 compared to BRD3 and BRD4. BBC0403 has the potential for osteoarthritis (OA) research .

HY-136571

GSK046 3 Publications Verification iBET-BD2	Epigenetic Reader Domain	Inflammation/Immunology
GSK046 (iBET-BD2), a chemical probe, is a potent, selective and orally active BD2 bromodomain inhibitor of the BET proteins, with IC₅₀s of 264 nM (BRD2 *BD2), 98 nM (BRD3* *BD2), 49 nM (BRD4* *BD2) and 214 nM (BRDT BD2*), respectively. GSK046 has immunomodulatory activity .

HY-13959

MS436 1 Publications Verification	Epigenetic Reader Domain	Cancer
MS436 is a new class of bromodomain inhibitor, exhibits potent affinity of an estimated K_i=30-50 nM for the BRD4 BrD1 and a 10-fold selectivity over the BrD2.

HY-134463

NHWD-870 1 Publications Verification	Epigenetic Reader Domain Apoptosis	Cancer
NHWD-870 is a potent, orally active and selective BET family bromodomain inhibitor and only binds bromodomains of BRD2, BRD3, BRD4 (IC₅₀=2.7 nM), and BRDT. NHWD-870 has potent tumor suppressive efficacies and suppresses cancer cell-macrophage interaction. NHWD-870 increases tumor apoptosis and inhibits tumor proliferation .

HY-13032B

Molibresib besylate 20+ Cited Publications GSK 525762C; I-BET 762 besylate	Epigenetic Reader Domain ERK	Cancer
Molibresib besylate (GSK 525762C; I-BET 762 besylate) is an orally active pan-BET inhibitor that targets and binds to **BRD2, BRD3, BRD4 and BRDT. By competitively occupying acetylated lysine binding sites, Molibresib besylate disrupts the interaction between BET proteins and chromatin, thereby effectively inhibiting MYC expression and target gene transcription. Molibresib besylate exhibits broad antiproliferative activity, which not only inhibits cancer cell growth and induces growth arrest, but also downregulates mitosis-related genes and upregulates the level of p-ERK1/2. When combined with MEK** inhibitors, Molibresib besylate shows a significant synergistic effect, reduces tumor burden in mouse models of leukemia, modulates the immune microenvironment and prolongs survival. Molibresib besylate is widely applicable to research related to acute myeloid leukemia, multiple myeloma, triple-negative breast cancer, small-cell lung cancer and various advanced refractory solid tumors ^[2] .

HY-120000

MS402 2 Publications Verification	Epigenetic Reader Domain	Inflammation/Immunology Cancer
MS402 is a BD1-selective BET BrD inhibitor with K_is of 77 nM, 718 nM, 110 nM, 200 nM, 83 nM, and 240 nM for *BRD4(BD1), BRD4(BD2), BRD3(BD1), BRD3(BD2), BRD2(BD1)* and *BRD2(BD2)*, respectively. MS402 blocks Th17 cell differentiation and ameliorates colitis in mice .

HY-112429

HJB97 2 Publications Verification	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Cancer
HJB97 is a high-affinity BET inhibitor with K_i values of 0.9 nM (BRD2 BD1), 0.27 nM (BRD2 *BD2), 0.18 nM (BRD3* BD1), 0.21 nM (BRD3 *BD2), 0.5 nM (BRD4* BD1), and 1.0 nM (BRD4 *BD2) . HJB97 can serve as a ligand for target protein (Ligands for Target Protein for PROTAC) for the development of PROTAC BET* degraders with antitumor activity . HJB97 can be used for the synthesis of BETd-260 (HY-101519).

HY-117286

(S)-JQ-35 TEN-010	Epigenetic Reader Domain Apoptosis	Neurological Disease Cancer
(S)-JQ-35 (TEN-010) is an orally active, blood-brain barrier-permeable bromodomain inhibitor that selectively targets the bromodomain and extra-terminal domain (BET) protein family (BRD4, BRD3, BRD2 and BRDT). (S)-JQ-35 blocks the activation of Myc gene expression by BRD4, thereby inhibiting cancer cell proliferation and promoting cancer cell apoptosis. (S)-JQ-35 can be used in research related to NUT midline carcinoma and neuroblastoma ^[2].

HY-149878

BD-9136	PROTACs Epigenetic Reader Domain	Cancer
BD-9136 is a potent and highly selective BRD4 PROTAC depressant. BD-9136 has low-nanomolar degradation potencies against BRD4 , and its degradation selectivity for BRD4 is 1000 times that of BRD2 and BRD3 proteins. BD-9136 has antitumor activity .(Pink: Desmethyl-QCA276 (HY-44103); Black: 3-(2-(4-Methylpiperazin-1-yl)ethyl)azetidin-3-ol; Blue: Thalidomide-4-OH (HY-103596))

HY-160528

IBG3 1 Publications Verification	Epigenetic Reader Domain Molecular Glues	Cancer
IBG3 is a Molecular glue degrader targeting *BRD2* and *BRD4, with DC₅₀* values of 8.6 pM and 6.7 pM, respectively. IBG3 binds simultaneously to the tandem bromodomains of BRD2/BRD4, induces intramolecular conformational changes, enhances the affinity of BRD2/BRD4 for DCAF16, and promotes ubiquitination and degradation. IBG3 is applicable to the research of chronic myeloid leukemia .

HY-153459

IBG1	Molecular Glues Epigenetic Reader Domain	Cancer
IBG1 is a molecular glue degrader targeting *BRD2* and *BRD4* (DC₅₀: 0.15 nM). IBG1 has no significant degradation effect on its paralogue *BRD3. IBG1 can inhibit the growth of cancer cells and can be used in tumor research. (Pink: BRD2/BRD4* Ligand (HY-111139); Black: Linker; Blue: DCAF15 ligand-1 (HY-W037495)) ^[2].

HY-103633

PROTAC BET Degrader-1 2 Publications Verification	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BET Degrader-1 is a PROTAC connected by ligands for Cereblon and BET, decreasing BRD2, BRD3, and BRD4 protein levels at low concentration.

HY-19760

I-BET282	Epigenetic Reader Domain	Inflammation/Immunology
I-BET282 is a pan-inhibitor of all eight BET bromodomains, and selectivity over other representative bromodomain-containing proteins. I-BET282 shows pIC₅₀s ranging 6.4-7.7 for BRD2 (BD1/BD2), BRD2 (BD1/BD), BRD3 (BD1/BD), and BRD4 (BD1/BD) .

HY-151593

dBRD4-BD1	PROTACs Epigenetic Reader Domain	Cancer
dBRD4-BD1 is a selective and durable *BRD4* degrader with an DC₅₀ value of 280 nM (D_max=77%). dBRD4-BD1 upregulates BRD2/3 protein level and shows low cytotoxicity than iBRD4-BD1 .

HY-153385

TMX1	Molecular Glues Epigenetic Reader Domain	Cancer
TMX1 is a covalent, selective *BRD4* molecular glue degrader. TMX1 binds to the JQ1-binding site of *BRD4BD2, forms covalent bonds with Cys58 of DCAF16* and Cys87 of GAK in a *BRD4BD2*-dependent template-assisted manner, stabilizes the *BRD4-TMX1-DCAF16* ternary complex, and promotes the ubiquitination of *BRD4* via the CRL4_DCAF16 ubiquitin ligase complex. TMX1 induces selective degradation of *BRD4, mild degradation of BRD2* and *BRD3*, as well as DCAF16-dependent cytotoxicity ^[2].

HY-112610

CF53	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CF53 is a highly potent, selective and orally active inhibitor of BET protein, with a K_i of <1 nM, K_d of 2.2 nM and an IC₅₀ of 2 nM for BRD4 BD1. CF53 binds to both the BD1 and BD2 domains of BRD2, BRD3, BRD4, and BRDT BET proteins with high affinities, very selective over non-BET bromodomain-containing proteins. CF53 shows potent anti-tumor activity both in vitro and in vivo .

HY-131061

BET bromodomain inhibitor 1	Epigenetic Reader Domain	Cancer
BET bromodomain inhibitor 1 is an orally active, selective bromodomain and extra-terminal (BET) bromodomain inhibitor with an IC₅₀ of 2.6 nM for BRD4. BET bromodomain inhibitor 1 binds to BRD2(2), BRD3(2), BRD4(1), BRD4(2), and BRDT(2) with high affinities (K_d values of 1.3 nM, 1.0 nM, 3.0 nM, 1.6 nM, 2.1 nM, respectively). bromodomain inhibitor 1 has anti-cancer activity .

HY-129917

KB02-JQ1 4 Publications Verification	PROTACs Epigenetic Reader Domain	Cancer
KB02-JQ1 is a highly selective and PROTAC-based *BRD4* degrader (molecular glue), but does not degrade BRD2 or BRD3. KB02-JQ1 promotes *BRD4* degradation by covalently modifying DCAF16 (E3 ligase) and can improve the durability of protein degradation in biological systems. JQ1 binds ubiquitin E3 ligase ligand KB02 via a linker to form KB02-JQ1 .

HY-145264

OARV-771	Epigenetic Reader Domain PROTACs	Cancer
OARV-771 is a VHL-based BET degrader (PROTAC) with improved cell permeability. OARV-771 shows DC₅₀s of 6, 1, and 4 nM for Brd4, Brd2 and Brd3, respectively .

HY-175678

*PROTAC BRD2* BD1 Degrader-1**	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD2 BD1 Degrader-1 (compound 21-1) is a potent and selective BRD2 BD1 PROTAC degrader. PROTAC BRD2 BD1 Degrader-1 induces the association of BRD2 BD1 and von Hippel–Lindau-elongin C-elongin B (VCB). (Pink: BRD2-BD1 Ligand (HY-175679); Blue: E3 ligase ligand (HY-125845); Black: Linker (HY-W069332)) .

HY-110215

XD14	Epigenetic Reader Domain	Cancer
XD14 is a potent BET inhibitor with antitumor effect. It binds to BRD2, BRD3, and BRD4 with K_ds of 170, 380, and 160 nM, respectively .

HY-114416

GS-626510	Epigenetic Reader Domain	Cancer
GS-626510 is a potent, and orally active BET family bromodomains inhibitor, with K_d values of 0.59-3.2 nM for BRD2/3/4, with IC₅₀ values of 83 nM and 78 nM foe BD1 and BD2, respectively .

HY-114504

RVX-297	Epigenetic Reader Domain	Inflammation/Immunology
RVX-297 is a potent, orally active BET bromodomain inhibitor with selectivity for *BD2. RVX-297 shows IC₅₀s of 0.08, 0.05, and 0.02 μM for BRD2(BD2), BRD3(BD2), and BRD*4(BD2), respectively. RVX-297 suppresses inflammatory gene expression in multiple immune cell types. RVX-297 is effective in acute inflammation and autoimmunity models ^[2].

HY-138563

GSK973	Epigenetic Reader Domain	Cancer
GSK973, a chemical probe, is a highly selective, orally bioavailable inhibitor of the *BD2s* (second bromodomains) of the BET family, with a pIC₅₀ of 7.8 and a pK_d of 8.7 for BRD4 BD2. GSK973 displays a 1600-fold selectivity for BRD4 BD2 over BRD4 BD1. GSK973 shows good potency against BRD2 BD2, BRD3 BD2, and BRDT BD2 (pIC₅₀=7.4~7.8; pK_d=8.3~8.5) .

HY-153894

SRX3177	CDK Epigenetic Reader Domain PI3K NF-κB SARS-CoV	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
SRX3177 is a triple inhibitor of CDK4/6, PI3K, and *BRD4, with IC₅₀s of <2.5 nM (CDK4), 3.3 nM (CDK6), 33 nM (BRD4 BD1), 89 nM (BRD4 BD2), 79 nM (PI3Kα), 83 nM (PI3Kδ), 3.18 μM (PI3Kγ) , respectively. SRX3177 blocks the interaction between the SARS-CoV-2 E protein* and the *BRD2/4* BD1 domain, restores E protein-attenuated NF-κB activity. SRX3177 exerts broad cytotoxic activity against cancer cells. SRX3177 can be used for the study of anti-SARS-CoV-2 and cancer ^[2].

HY-147046

ET-JQ1-OH	Epigenetic Reader Domain Ligands for Target Protein for PROTAC	Cancer
ET-JQ1-OH is an allele-specific BET inhibitor. ET-JQ1-OH can serve as a Ligand for Target Protein for PROTAC, and is used for the development and design of PROTAC Brd4 degraders, such as AB3145 (HY-180923).

HY-15743A

(R)-Birabresib 1 Publications Verification (R)-OTX-015; (R)-MK-8628	Drug Isomer	Cancer
(R)-Birabresib is the isomer of Birabresib (HY-15743), and can be used as an experimental control. Birabresib (OTX-015) is a potent bromodomain (BRD2/3/4) inhibitor with IC₅₀s ranging from 92 to 112 nM.

HY-130612

*PROTAC BRD2/BRD4 degrader-1*	Epigenetic Reader Domain PROTACs	Cancer
PROTAC BRD2/BRD4 degrader-1 (compound 15) is a potent and selective BET protein *BRD4* and *BRD2* degrader, connected by ligands for Cereblon and BET. PROTAC BRD2/BRD4 degrader-1 rapidly induces reversible, long-lasting, and unexpectedly selective removal of BRD4 and BRD2 over BRD3. It effectively inhibits solid tumors with low cytotoxic effect. PROTAC BRD2/BRD4 degrader-1 is composed of the BET inhibitor, a linker, and the ligand thalidomide for cereblon (CRBN)/cullin 4A .

HY-130813

BET-IN-6	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Cancer
BET-IN-6 is a potent and high affnity *BRD2/BRD4* inhibitor. BET-IN-6 is the ligand for target protein BRD2/4, and is used for the systhesis of PROTAC BRD2/BRD4 degrader-1 (HY-130612) .

HY-138623

GSK789	Epigenetic Reader Domain TNF Receptor Interleukin Related	Inflammation/Immunology Cancer
GSK789 is a selective inhibitor of BET BD1. GSK789 inhibits the growth of leukemia cell lines. GSK789 inhibits LPS-stimulated production of MCP-1, TNFα and IL-6 in human whole blood. GSK789 exhibits antiproliferative, anti-inflammatory and immunomodulatory activities. GSK789 can be used in research related to cancers such as leukemia, as well as inflammatory and immune diseases .

HY-168635

SJ46420	PROTACs Epigenetic Reader Domain	Cancer
SJ46420, a SJ46421 (HY-168634) pro-drug variant, is a potent and selective BRD3 PROTAC degrader. SJ46420 degrads BRD3 in a KLHDC2-dependent manner, thereby partially reducing the levels of BRD2 or BRD4 (Pink: ligand for target protein (HY-13030); Black: linker (HY-20797); Blue: E3 ligase ligand (HY-159973)) .

HY-175679

BRD2 BD1 ligand-1	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Cancer
BRD2 BD1 ligand-1 is a potent BRD2 BD1 ligand (Ligands for Target Protein for PROTACs) can be used in the synthesis of PROTAC BRD2 BD1 Degrader-1 (HY-175678) .

HY-RS01599

BRD2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
BRD2 Rat Pre-designed siRNA Set A contains three designed siRNAs for BRD2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

BRD2 Rat Pre-designed siRNA Set A BRD2 Rat Pre-designed siRNA Set A

HY-RS01597

BRD2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
BRD2 Human Pre-designed siRNA Set A contains three designed siRNAs for BRD2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

BRD2 Human Pre-designed siRNA Set A BRD2 Human Pre-designed siRNA Set A

HY-RS01598

Brd2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Brd2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Brd2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Brd2 Mouse Pre-designed siRNA Set A Brd2 Mouse Pre-designed siRNA Set A

HY-170900

SJ44236	PROTACs Epigenetic Reader Domain	Cancer
SJ44236 is the PROTAC degrader for BET that degrades *BRD2* (DC₅₀ = 0.127 nM), *BRD3* and *BRD4. SJ44236 exhibits cytotoxicity in cell MV4-11 and HD-MB03 with IC₅₀*s of 0.12 nM and 0.92 nM. SJ44236 downregulates the expression of c-Myc, upregulates the expression of p53. SJ44236 exhibits a good orally bioavailability of 45% in mice . (Pink: ligand for target protein JQ-1 carboxylic acid (HY-78695); Black: linker (HY-W012935); Blue: ligand for E3 ligase Cereblon E3 ligase Ligand 54 (HY-W890189))

HY-130814

Thalidomide-NH-C4-NH2 TFA	E3 Ligase Ligand-Linker Conjugates Autophagy Apoptosis	Cancer
Thalidomide-NH-C4-NH2 TFA (compound 29c) is an E3 ligase ligand-linker conjugate, and incorporates the Thalidomide based cereblon ligand and a linker. Thalidomide-NH-C4-NH2 TFA is used in PROTAC BRD2/BRD4 degrader-1 (HY-130612). PROTAC BRD2/BRD4 degrader-1 is a potent and selective BET protein BRD4 and BRD2 degrader .

HY-13031

GW 841819X	Epigenetic Reader Domain Apolipoprotein	Cancer
GW 841819X is a potent inducer of the ApoA1 report gene, with an EC₁₇₀ of 0.22 µM, and its pIC₅₀ for *Brd2/3/4* is 5.9/6.2/6.3 .

HY-15743R

Birabresib (Standard) OTX-015 (Standard); MK-8628 (Standard)	Reference Standards Epigenetic Reader Domain	Cancer
Birabresib (Standard) is the analytical standard of Birabresib. This product is intended for research and analytical applications. Birabresib (OTX-015) is a potent bromodomain (BRD2/3/4) inhibitor with IC₅₀s ranging from 92 to 112 nM.

HY-168634

SJ46421	PROTACs Epigenetic Reader Domain	Cancer
SJ46421 is a (+)-JQ-1 (HY-13030) based KLHDC2-BRD3 PROTAC protein degrader. SJ46421 induces cooperative ternary complexes with KLHDC2 and BRD3BD2, with an IC₅₀ of 7.8 nM. SJ46421 selectively inhibits KLHDC2 substrate ubiquitylation. SJ46421 promotes polyubiquitylation of the BD2 domain from BRD2, BRD3, or BRD4. SJ46421 possesses poor cell permeability. (Pink: ligand for target protein (HY-13030); Black: linker (HY-20797); Blue: E3 ligase ligand (HY-168536)) .

HY-175680

Boc-4-(3-oxobutyl)piperidine-(S,R,S)-AHPC	E3 Ligase Ligand-Linker Conjugates	Cancer
Boc-4-(3-oxobutyl)piperidine-(S,R,S)-AHPC is an E3 ligase ligand-linker conjugatecan be used in the synthesis of PROTAC BRD2 BD1 Degrader-1 (HY-175678) .

Host:	Mouse (2) Rabbit (1)
Reactivity:	Human (3) Rat (2)
Application:	IHC-P (1) ICC/IF (1) IF-Tissue (1) IHC-F (1) WB (3) FC (3) ELISA (2)
Isotype:	IgG (1) IgG2b (2)
Conjugation:	Non-conjugated (3)
Clonality:	Monoclonal (2) Recombinant (1)
Modification:	Unmodified (2)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P80037

	BRD2 Antibody (YA579)	WB, IHC-P, IHC-F, IF-Tissue, FC, ICC/IF	Human
	BRD2 Antibody (YA579) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to BRD2.

HY-P84213

	BRD2 Antibody (YA3910) FSH; NAT; RNF3; FSRG1; RING3; D6S113E; O27.1.1	WB, FC, ELISA	Human, Rat
	BRD2 Antibody (YA3910) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to BRD2.

HY-P84213A

	BRD2 Antibody (YA3910)(PBS only) FSH; NAT; RNF3; FSRG1; RING3; D6S113E; O27.1.1	WB, FC, ELISA	Human, Rat
	BRD2 Antibody (YA3910) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to BRD2.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-182371

BRD4 ligand 15		Alkynes
BRD4 ligand 15 (compound 5) is a *BRD4* ligand and alkyne-modified chalcone derivative, which serves as a building block for the synthesis of *BRD4*-targeting PROTAC TKP-5 (HY-182370) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: